Trial Profile
A retrospective,multicenter study investigating factors associated with efficacy of Sorafenib in patients with metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Apr 2017
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 06 Apr 2017 New trial record